Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Posted on by Neuroscientists

Assoc. Prof. Dr. Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska,  Department of Neurology and Neurosurgery, School of Medicine, University of Warmia and Mazury, Poland.

Dr. Izabela Małysz-Cymborska is a distinguished biomedical researcher and Associate Professor in Neurosurgery at the University of Warmia and Mazury, Poland. Her academic path began with a Master’s in Biology and culminated in a Ph.D. focused on hormonal mechanisms, followed by a Habilitation in Medicine. Her research spans neuroregeneration, stem cell therapy, and immunomodulatory strategies for neurological diseases such as ALS and stroke. She has led and contributed to nationally funded projects like NanoTech4ALS, Explore Me, and her current OPUS-funded investigation using a swine model for stroke therapy. Her interdisciplinary approach bridges molecular biology, reproductive science, and clinical neuroscience, demonstrating a rare ability to translate foundational research into therapeutic innovation.

Profile

Google Scholar

🎓 Early Academic Pursuits

Dr. Izabela Małysz-Cymborska embarked on her academic journey with a deep-rooted interest in biological sciences. Born on September 21, 1985, in Poland, she pursued her undergraduate studies at the University of Warmia and Mazury in Olsztyn, earning a Master of Science degree in Biology in 2009. Her passion for advanced biomedical research led her to the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, where she completed her Ph.D. in 2015. Her doctoral research, grounded in hormonal action mechanisms, laid the foundation for her future contributions to neurobiology and regenerative medicine.

🧠 Professional Endeavors in Neuroscience

Dr. Małysz-Cymborska’s postdoctoral and professional journey has been largely rooted in neuroscientific investigation, with a special focus on neuroregeneration and stroke therapy. Since 2021, she has held the position of Associate Professor in the Department of Neurosurgery at the University of Warmia and Mazury. Her early postdoctoral fellowships (2015–2018) focused on pioneering work in the application of glial progenitors and stem cells in neurological disorders like ALS. These formative experiences not only enriched her research trajectory but also provided a vital bridge between animal studies and translational medicine.

🧪 Research Focus and Scientific Contributions

Dr. Małysz-Cymborska’s research portfolio reflects a consistent dedication to understanding complex neural pathologies and their treatment through regenerative approaches. She has led and contributed to several national and international projects, including NanoTech4ALS, which investigated MRI-monitored transplantation techniques using hydrogel carriers for ALS treatment. Her current role as Principal Investigator in the OPUS-funded project explores an endovascular model of stroke in swine, opening new therapeutic pathways for immunomodulation. She has also delved into reproductive biology, investigating the influence of gonadotropins on prostaglandin synthesis and the function of the corpus luteum, showcasing her multidisciplinary expertise.

🧬 Bridging Regeneration and Technology

A major hallmark of Dr. Małysz-Cymborska’s work is the integration of regenerative medicine and cutting-edge biomedical technologies. Her involvement in Explore Me and NanoTech4ALS demonstrated her commitment to merging cellular therapy with advanced biomaterials and imaging. These projects explored the therapeutic potential of mesenchymal stem cells and human glial progenitors for neurodegenerative conditions, reflecting her drive to push boundaries in translational medicine and neurosurgery.

🏅 Accolades and Recognition

Dr. Małysz-Cymborska’s scientific accomplishments were recognized through her Habilitation Degree in Medicine, awarded in 2022 by the University of Warmia and Mazury—a prestigious academic achievement in Poland that underscores her contributions to the medical sciences. Additionally, her appointment as the Dean’s representative for animal experiments between 2018 and 2019 further illustrates the trust and respect she commands within her institution and the research community.

🌍 Impact and Influence in Translational Neuroscience

Her work has had significant implications not only in Poland but also across the global neuroscience landscape. By focusing on models that simulate real-world human neurological disorders, such as swine models for stroke and ALS, she has established platforms that can more accurately predict treatment outcomes in humans. Her collaborative efforts within national strategic medical programs have enriched the broader field of translational neuroscience, particularly in immune response modulation and neural repair mechanisms.

🔮 Legacy and Future Contributions

As her OPUS project continues until 2025, Dr. Izabela Małysz-Cymborska is poised to deliver crucial insights into stroke immunotherapy. Her legacy lies in her ability to traverse boundaries between endocrinology, neurobiology, and regenerative therapy—crafting a unique niche that advances both fundamental science and clinical application. With a promising trajectory ahead, she is set to influence future protocols in neurovascular therapy, offering hope to patients with currently untreatable conditions.

Publication

  • Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies
    Authors: JM Oliveira, L Carvalho, J Silva-Correia, S Vieira, M Majchrzak, …
    Year: 2018

 

  • Advances in bioinks and in vivo imaging of biomaterials for CNS applications
    Authors: EP Oliveira, I Malysz-Cymborska, D Golubczyk, L Kalkowski, …
    Year: 2019

 

  • The role of glia in canine degenerative myelopathy: relevance to human amyotrophic lateral sclerosis
    Authors: D Golubczyk, I Malysz-Cymborska, L Kalkowski, M Janowski, JR Coates, …
    Year: 2019

 

  • Methacrylated gellan gum and hyaluronic acid hydrogel blends for image-guided neurointerventions
    Authors: S Vieira, P Strymecka, L Stanaszek, J Silva-Correia, K Drela, …
    Year: 2020

 

  • MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals
    Authors: I Malysz-Cymborska, D Golubczyk, L Kalkowski, A Burczyk, M Janowski, …
    Year: 2018

 

  • Endovascular model of ischemic stroke in swine guided by real-time MRI
    Authors: D Golubczyk, L Kalkowski, J Kwiatkowska, M Zawadzki, P Holak, J Glodek, …
    Year: 2020

 

  • Expression of the vascular endothelial growth factor receptor system in porcine oviducts after induction of ovulation and superovulation
    Authors: I Małysz-Cymborska, A Andronowska
    Year: 2014

 

  • Rabbit model of human gliomas: implications for intra-arterial drug delivery
    Authors: H Qin, M Janowski, MS Pearl, I Malysz-Cymborska, S Li, CG Eberhart, …
    Year: 2017

 

  • Two in one: use of divalent manganese ions as both cross-linking and MRI contrast agent for intrathecal injection of hydrogel-embedded stem cells
    Authors: L Kalkowski, D Golubczyk, J Kwiatkowska, P Holak, K Milewska, …
    Year: 2021

 

  • Effect of hCG and eCG treatments on Prostaglandins Synthesis in the Porcine Oviduct
    Authors: I Małysz‐Cymborska, AJ Ziecik, A Waclawik, A Andronowska
    Year: 2013

 

🧾 Conclusion

Dr. Małysz-Cymborska’s career reflects a compelling fusion of scientific curiosity, clinical relevance, and academic rigor. With notable achievements in regenerative medicine and translational neuroscience, she continues to shape the future of therapeutic interventions for complex neurological disorders. Her ongoing research promises to pave the way for advanced stroke treatments and immune-based neurotherapies, cementing her role as a key contributor to modern biomedical science.

John Vincent Sanchez Orti | Biomarkers in Neurocognition | Young Scientist Award

Posted on by Neuroscientists

Dr. John Vincent Sanchez Orti | Biomarkers in Neurocognition | Young Scientist Award

Dr. Joan Vicent Sánchez Ortí, Health research institute,  Spain.

Joan Vicent Sánchez Ortí is a Clinical Psychologist and Neuropsychologist currently working as a Research Technician at the Instituto de Investigación Sanitaria – INCLIVA. He is also a predoctoral researcher affiliated with CIBERSAM (Group 24, Universitat de València). His academic background includes a Bachelor’s degree in Psychology (2016), a Master’s in General Health Psychology (2019), and a Master’s in Basic and Applied Neurosciences (2021), all from Universitat de València. He is currently pursuing a Ph.D. in Medicine.

Profile

Google Scholar

Orcid

🧠 A Passion for Understanding the Mind

Joan Vicent Sánchez Ortí was born on August 6, 1994, with an innate curiosity about the complexities of human cognition. From an early age, he displayed a deep interest in psychology and neuroscience, which led him to pursue an academic path dedicated to unraveling the mysteries of the brain. His journey began at the Universitat de València, where he obtained his degree in Psychology in 2016. Motivated by his growing fascination with neuropsychology, he continued his studies, earning a Master’s in General Health Psychology in 2019 and a Master’s in Basic and Applied Neurosciences in 2021. His dedication to advancing medical science led him to enroll in an official Doctorate Program in Medicine at the same institution.

🏥 Bridging Psychology and Neuroscience in Professional Practice

Currently serving as a Neuropsychologist and Research Technician at the Health Research Institute (INCLIVA) in Spain, Joan Vicent plays a vital role in understanding cognitive impairments associated with severe mental disorders. His affiliation with the Biomedical Research Center in Mental Health Network (CIBERSAM) – Group 24 at the Universitat de València has allowed him to contribute significantly to groundbreaking studies. His expertise lies in assessing neurocognitive deficits, biomarkers, and epigenetic factors, aiming to enhance the diagnosis and treatment of psychiatric and neurological conditions.

🔬 Advancing Research in Neurocognitive Deficits and Mental Health

Joan Vicent’s research delves into the intricate connections between brain function, cognition, and mental health. His studies focus on identifying early biomarkers of cognitive decline, exploring epigenetic influences, and evaluating social functioning and quality of life in patients suffering from severe mental disorders. His contributions have been instrumental in improving the understanding of conditions such as schizophrenia, bipolar disorder, and neurodegenerative diseases, providing valuable insights for clinical interventions.

🏆 Recognized for Excellence in Neuroscience and Psychology

Through his commitment to scientific discovery, Joan Vicent has garnered recognition in the field of neuroscience and psychology. His contributions to neuropsychology and mental health research have positioned him as a promising figure in cognitive science. His work is widely acknowledged for its impact on the development of new therapeutic approaches and diagnostic techniques. With a strong academic and research background, he continues to be an influential voice in the study of cognitive impairment.

🌍 Impacting Lives Through Mental Health Research

Beyond academic achievements, Joan Vicent’s work has real-world implications, improving the quality of life for individuals facing cognitive challenges. His research contributes to developing more effective treatments, enhancing diagnostic accuracy, and fostering a better understanding of mental disorders. Through his role at INCLIVA and CIBERSAM, he actively collaborates with interdisciplinary teams, ensuring that his findings are translated into clinical practice, ultimately benefiting patients and healthcare professionals alike.

🚀 Paving the Way for Future Innovations in Neuropsychology

With a strong foundation in psychology, neuroscience, and medicine, Joan Vicent remains dedicated to pushing the boundaries of cognitive research. His ongoing studies aim to integrate cutting-edge techniques in neuroimaging, genetics, and artificial intelligence to refine the understanding of neurocognitive disorders. His ambition is to contribute to the development of personalized medicine, where treatments are tailored to an individual’s neurobiological and psychological profile, revolutionizing mental healthcare.

🔮 A Vision for a Healthier, Cognitively Resilient Future

Looking ahead, Joan Vicent Sánchez Ortí envisions a world where mental health is better understood, diagnosed, and treated with precision. His dedication to neuropsychology and cognitive research will continue to shape the future of mental healthcare, inspiring new generations of scientists and clinicians. As he advances in his career, his unwavering commitment to improving lives through research stands as a testament to his passion and perseverance in the field of neuroscience.

Publication

  • Manual motor speed dysfunction as a neurocognitive endophenotype in euthymic bipolar disorder patients and their healthy relatives. Evidence from a 5-year follow-up study
    P Correa-Ghisays, V Balanzá-Martínez, G Selva-Vera, J Vila-Francés, …
    2017

 

  • Grip Strength, Neurocognition, and social functioning in people With Type-2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia
    M Aliño-Dies, JV Sanchez-Orti, P Correa-Ghisays, V Balanzá-Martinez, …
    2020

 

  • Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study
    P Correa-Ghisays, JV Sánchez-Ortí, R Ayesa-Arriola, E Setién-Suero, …
    2019

 

  • Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders
    JV Sanchez‐Orti, V Balanzá‐Martinez, P Correa‐Ghisays, G Selva‐Vera, …
    2022

 

  • Immune–Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and …
    M Garés-Caballer, JV Sánchez-Ortí, P Correa-Ghisays, …
    2022

 

  • Probiotic, prebiotic, synbiotic and fermented food supplementation in psychiatric disorders: A systematic review of clinical trials
    C Ribera, JV Sánchez-Ortí, G Clarke, W Marx, S Mörkl, …
    2024

 

  • Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study
    P Correa-Ghisays, JV Sanchez-Orti, V Balanza-Martinez, G Selva-Vera, …
    2022

 

  • Inflammation and lipid metabolism as potential biomarkers of memory impairment across type 2 diabetes mellitus and severe mental disorders
    JV Sanchez-Orti, P Correa-Ghisays, V Balanza-Martinez, G Selva-Vera, …
    2023

 

  • MICEmi: A method to identify cognitive endophenotypes of mental illnesses
    P Correa-Ghisays, JV Sanchez-Orti, V Balanza-Martinez, I Fuentes-Dura, …
    2022

 

  • Specific immune-inflammatory profiles and neurocognitive deficits predict illness trajectories in people with type 2 diabetes mellitus or psychiatric disorders
    JV Sanchez-Orti, P Correa-Ghisays, V Balanza-Martinez, G Selva-Vera, …
    2025

 

Conclusion 🎯

Joan Vicent Sánchez Ortí’s dedication to neuroscience and mental health research positions him as an influential figure in the field. His expertise bridges psychology, medicine, and genetics, offering innovative solutions for cognitive disorders. With a strong commitment to improving lives through research, his work has already made a meaningful impact and will continue to shape the future of mental healthcare, neuropsychology, and personalized medicine. As he advances in his career, his passion and contributions will undoubtedly lead to groundbreaking discoveries in cognitive science.

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.